Clinical Trial Update: Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on low-dose Interleukin-2 treatment for Macrophage Activation Syndrome (Phase 1/Phase 2), with status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macrophage Activation Syndrome

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Macrophage Activation Syndrome | Phase 1, Phase 2 | Status: UNKNOWN